Using N1E-115 neuroblastoma cells as an experimental model, we have examined if four commonly used i.v. anaesthetic induction agents interact with 5-HT 3 receptors. Specifically, we tested the hypothesis that the antiemetic effects of propofol may result from 5-HT 3 receptor antagonism. Binding of tropisetron (a 5-HT 3 selective reference compound), etomidate, ketamine, thiopentone and propofol to 5-HT 3 receptors was assessed by measuring the displacement of ). With the exception of thiopentone these effects were outside the clinical range and suggest that anaesthetic agents are unlikely to interact directly with 5-HT 3 receptors, and that other mechanism(s) must underlie the antiemetic effects of propofol. (Br. J. Anaesth. 1995: 76: 271-273) 
Nausea and vomiting are distressing side effects of general anaesthesia. The pathogenesis of postoperative nausea and vomiting is multifactorial [1] . It has been shown that the 5-HT 3 receptor, a member of the ligand-gated, ion channel family [2] , is densely located in areas known to be involved in the emetic reflex and could be the key receptor involved in nausea and vomiting [3] . The importance of the 5-HT 3 receptor has been demonstrated in clinical practice where 5-HT 3 antagonists have been used to suppress nausea and vomiting caused by emetic agents [4, 5] . Indeed, selective 5-HT 3 receptor antagonists appear to prevent acute emesis by blocking the initiation of the emetic reflex produced via 5-hydroxytryptamine (5-HT) release from enterochromaffin cells in the gastrointestinal tract in addition to blocking 5-HT 3 receptors in the brain [6] .
General anaesthesia with propofol is associated with a decreased incidence of early postoperative nausea and vomiting [7] [8] [9] . However, it is unlikely that propofol exerts its antiemetic action via sedation as the duration of its antiemetic effect outlasts its hypnotic effect. It has been suggested recently that propofol has significant direct antiemetic properties [10] . While the exact mechanism of the antiemetic action of propofol is unknown we have recently shown that these effects are unlikely to result from dopamine D2 receptor antagonism [11] . Using the murine neuroblastoma cell line, N1E-115, as a 5-HT3 expression system [12] , we have examined the effects of four commonly used i.v. anaesthetic induction agents on the binding of [ 
Materials and methods
Mouse neuroblastoma cells of the clone N1E-115 were cultured in Dulbecco's modified Eagle's medium. The growth medium was supplemented with 10 % fetal calf serum, with the antibiotics penicillin 100 u. ml 91 , streptomycin 100 g ml 91 and Fungizone 2.5 g ml
91
. Cells were cultured to subconfluence in a humidified atmosphere containing 5 % carbon dioxide at 37 ЊC and were passaged every 5-7 days with re-feeding every third day.
Drugs used included: propofol (Zeneca Pharmaceuticals, Macclesfield, UK, lot: 71013/91A) solubilized in dimethylsulphoxide (DMSO); etomidate hydrochloride (Janssen Pharmaceuticals, Bucks, UK); sodium thiopentone (Rhone-Poulenc Rorer, Dagenham, UK, batch 62800) solubilized at 1 mmol litre 91 in NaOH 1.0 mol litre 91 (when this was added to the binding assay buffer, 9 100 dilution, the pH remained unchanged at 7. 
Results

Binding of [
3 H]BRL 43694 was displaced in a dose dependent manner by the 5HT3 selective reference compound, tropisetron. The calculated affinity (1.7 nmol litre) was consistent with previous reports [15] [16] [17] . In addition, there was a dose-dependent displacement of [ 3 H]BRL 43694 by the four anaesthetic agents tested. The curves shown in figure 1 and analysed in table 1 are based on maximum displacement of 100 %, although this was not achieved experimentally. The rank order potency was etomidate ജ ketamine 9 thiopentone 9 propofol. DMSO, the vehicle for propofol, produced : 5 % displacement of [ With the exception of thiopentone, these effects fell outside the clinically relevant serum concentrations [18] [19] [20] [21] .
Discussion
We have demonstrated that four commonly used i.v. anaesthetic induction agents exert little direct effect on endogenous 5-HT 3 receptors in a cultured neuronal cell line, N1E-115. There was some overlap with the K i for thiopentone and the observed peak serum concentration. However, these studies do not enable predictions to be made as to whether thiopentone is acting as an agonist (emetic) or antagonist (antiemetic). More importantly, our studies suggested that the reported antiemetic action of propofol [7] [8] [9] is unlikely to be caused by 5-HT 3 receptor block as the K i values of propofol exceeded the peak plasma and brain [22] anaesthetic concentrations. In addition, the K i was approximately 25-fold greater than plasma propofol concentrations at subhypnotic doses, where a significant antiemetic action can be demonstrated [7] [8] [9] . However, it should be noted that there may be interspecies variation in the 5-HT3 receptor and consequently K i values in mouse cells may not be a true reflection of those in humans.
Our results are at variance with the findings of a recent study of the action of i.v. anaesthetics with the 5-HT3 receptor by Barann and colleagues [23] , who found that i.v. anaesthetics inhibited 5-HT-induced flux of 14 C-guanidinium through the cation channel of the 5-HT3 receptor. The rank order of potency in their study was propofol 9 etomidate 9 thiopentone 9 ketamine (in our study we found propofol the least potent). This functional block of the 5-HT3 receptor by anaesthetic drugs may result from channel block rather than receptor antagonism, but suggests that direct 5-HT3 receptor antagonism may not be the only way to reduce emesis, in that "downstream" functional block may also be important. As the inhibition of 14 C-guanidinium influx [23] was non- competitive, this modifies the general conclusions of our study. While there does not appear to be 5-HT3 receptor block, channel inhibition by anaesthetic agents appears to be a viable and potent [23] mechanism for producing antiemesis. However, thiopentone and etomidate do not appear to exert significant antiemetic action but still reduce 5-HT3 function at clinically relevant doses.
